GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Net Change in Cash

RKVTF (Rakovina Therapeutics) Net Change in Cash : $-1.82 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Rakovina Therapeutics's Net Change in Cash for the three months ended in Sep. 2024 was $-1.03 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.82 Mil.

Rakovina Therapeutics Net Change in Cash Historical Data

The historical data trend for Rakovina Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Net Change in Cash Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Net Change in Cash
2.20 -1.41 -0.34

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.28 -0.19 -0.32 -1.03

Rakovina Therapeutics Net Change in Cash Calculation

Rakovina Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.388+0+1.044+0
=-0.34

Rakovina Therapeutics's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.031+0+0+0
=-1.03

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Net Change in Cash
Comparable Companies
TSXV:CYTO TSX:RVX TSXV:SBM TSXV:KNE XCNQ:BIOV XCNQ:BETR XCNQ:PREV XCNQ:BLAB TSX:CSCI XCNQ:PHRM VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
RKV:Canada
Address
595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5
Website
https://www.rakovinatherapeutics.com
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.